Loading...
Comparative safety of BRAF and MEK inhibitors (vemurafenib, dabrafenib and trametinib) in first-line therapy for BRAF-mutated metastatic melanoma
A retrospective observational study was conducted on patients diagnosed with serine/threonine-protein kinase B-Raf (BRAF)-mutated metastatic melanoma, who underwent first-line therapy with BRAF and mitogen-activated protein kinase kinase (MEK) inhibitors (vemurafenib, dabrafenib or a combination of...
Na minha lista:
| Udgivet i: | Mol Clin Oncol |
|---|---|
| Main Authors: | , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
D.A. Spandidos
2016
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5038159/ https://ncbi.nlm.nih.gov/pubmed/27699043 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/mco.2016.978 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|